Nicolás Dauby - Infectious Diseases

Author Information

Nicolas Dauby is a prolific researcher in the field of infectious diseases, affiliated with the Department of Infectious Diseases at the Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB) in Brussels, Belgium. His work primarily focuses on infectious diseases, with a significant contribution to understanding and managing diseases such as COVID-19, tuberculosis, and other viral infections.

Research Contributions

Nicolas Dauby has made substantial contributions to the field of infectious diseases through his research on various topics, including the immunological aspects of infectious diseases and the evaluation of treatment strategies. In 2022 alone, he published several papers that addressed critical issues such as the impact of tocilizumab on inflammatory cytokines in COVID-19 patients, the evaluation of unproven COVID-19 treatments, and the immune response to yellow fever vaccination in people living with HIV. His work also extends to the optimization of diagnostic tools for tuberculosis and the economic evaluation of pediatric immunization programs in Belgium.

Aliases

Nicolas Dauby is known by several aliases, including N Dauby and N. Dauby. These variations are often used across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Papers	147
H-index	23
Total Citations	2176

Publications:

Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6.

DOI: 10.1089/vim.2021.0111

Year: 2022

From hydroxychloroquine to ivermectin: how unproven “cures” can go viral

DOI: 10.1016/j.cmi.2022.01.008

Year: 2022

Immuno-Diagnosis of Active Tuberculosis by a Combination of Cytokines/Chemokines Induced by Two Stage-Specific Mycobacterial Antigens: A Pilot Study in a Low TB Incidence Country

DOI: 10.3389/fimmu.2022.842604

Year: 2022

An instrument to measure psychosocial determinants of health care professionals' vaccination behavior: Validation of the Pro-VC-Be questionnaire.

DOI: 10.1080/14760584.2022.2046467

Year: 2022

Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.

DOI: 10.1093/jtm/taac024

Year: 2022

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

DOI: 10.1183/13993003.01724-2021

Year: 2022

Functional reprogramming of monocytes in acute and convalescent severe COVID-19 patients.

DOI: 10.1172/jci.insight.154183

Year: 2022

Antimicrobial susceptibly testing determined by Alfred 60/AST (Alifax®) in a multi-sites' lab: performance's evaluation and optimisation of workflow.

DOI: 10.1016/j.mimet.2022.106433

Year: 2022

Optimal Detection of Latent Mycobacterium tuberculosis Infection by Combined Heparin-Binding Hemagglutinin (HBHA) and Early Secreted Antigenic Target 6 (ESAT-6) Whole-Blood Interferon Gamma Release Assays

DOI: 10.1128/jcm.02443-21

Year: 2022

POSC105 Economic Evaluation of the Pediatric Immunization Program in Belgium

DOI: 10.1016/j.jval.2021.11.510

Year: 2022

Why is Understanding Airborne Transmission Important?

What to Do If Infection is Suspected Post-Transfusion?

What diseases are caused by Flaviviridae?

How are Antimicrobials Administered?

How Do APCs Capture and Process Antigens?

What is the Global Impact of Zika Virus?

What are the Risk Factors for HAIs?

What Are the Challenges in Genomic Studies of Infectious Diseases?

How is PCR Used in Epidemiological Studies?

What is the Warburg Effect?

Partnered Content Networks

Relevant Topics